The Ultimate Pick For The Next Decade Novo Nordisk Prices In Too Few New Patients For GLP-1 Currently Hims & Hers gains peptide facility; shares tumble on semaglutide shortage end Hims & Hers ...

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are ...

Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...

Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with addiction, Martin Holst Lange, the Danish pharma’s head of development ...

Novo Nordisk A/S (NYSE: NVO) has declared that its GLP-1 drugs for chronic obesity, under the brands Ozempic and Wegovy, are no longer in short supply. This caused the United States Food and Drug ...

The home shipments — which will be fulfilled by CenterWell Pharmacy — include Wegovy injections of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg.

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.